Physician profile
Jeffrey Muler
NPI 1285631739
$883.58
in general payments reported to CMS, 2019-2025
21 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $85.14 · 2021: $54.28 · 2022: $35.26 · 2023: $182 · 2024: $97.96 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414 · Education: $76.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.03 |
| Education | $76.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $195.58 | 2019-2025 | |
| Abbvie INC. | $112.11 | 2019 | |
| Pfizer INC. | $80.42 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $62.93 | 2025 | Enhertu |
| Merck Sharp & Dohme LLC | $57.26 | 2019 | |
| Celgene Corporation | $48.66 | 2019-2020 | |
| Daiichi Sankyo INC. | $43.04 | 2023-2024 | Enhertu |
| Incyte Corporation | $33.85 | 2020-2023 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $28.86 | 2020-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $26.62 | 2021 | |
| Adaptive Biotechnologies Corporation | $21.70 | 2023 | Clonoseq |
| Amgen INC. | $20.76 | 2020 | |
| Emd Serono, INC. | $19.88 | 2023 | Tepmetko |
| G1 Therapeutics, INC. | $19.39 | 2023 | Cosela |
| Regeneron Healthcare Solutions, INC. | $19.14 | 2023 | Libtayo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $18.38 | 2023 | Foundationone Cdx |
| Lilly USA, LLC | $17.12 | 2020 | |
| Puma Biotechnology, INC. | $16.33 | 2025 | |
| Genzyme Corporation | $15.74 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.89 | 2023 | Reblozyl |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Muler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.